Skip to main content

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  225.72
-4.58 (-1.99%)
AAPL  272.00
+2.30 (0.85%)
AMD  261.05
-3.28 (-1.24%)
BAC  53.26
+0.68 (1.28%)
GOOG  283.79
+8.62 (3.13%)
META  674.26
-77.41 (-10.30%)
MSFT  526.58
-14.97 (-2.76%)
NVDA  204.07
-2.97 (-1.43%)
ORCL  262.43
-12.87 (-4.67%)
TSLA  444.60
-16.91 (-3.66%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.